FY2025 · period end Dec '25 · from the 10-K filed Feb 26, 2026
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $274.90B | $247.12B | $195.26B | $180.52B | $174.07B |
| Gross Profit | $59.91B | $64.61B | $61.46B | $55.68B | $56.52B |
| Operating Income | $9.20B | $9.42B | $8.54B | $8.45B | $7.94B |
| Net Income | $5.96B | $3.43B | $5.16B | — | — |
| EPS (Diluted) | $22.18 | $12.12 | $17.39 | $21.41 | $15.75 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $157.92B | $155.88B | $152.76B | $143.88B | $154.89B |
| Total Liabilities | $116.05B | $114.64B | $106.41B | $99.13B | $107.70B |
| Stockholders' Equity | $41.87B | $41.24B | $46.24B | $44.69B | $46.98B |
| Cash & Equivalents | $7.68B | $7.55B | $7.82B | $5.92B | $5.08B |
| Total Debt | $30.87B | $28.94B | $28.16B | $28.10B | $31.13B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $9.60B | $10.36B | $11.81B | $8.66B | $7.19B |
| Capital Expenditures | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | 21.8% | 26.1% | 31.5% | 30.8% | 32.5% |
| Operating Margin | 0.0% | 0.0% | 0.0% | 0.0% | 4.6% |
| Net Margin | 0.0% | 0.0% | 0.0% | 0.2% | — |
| Return on Equity | 14.3% | 7.9% | 98.7% | 85.7% | — |
| Return on Assets | 3.8% | 2.2% | 30.2% | 26.3% | — |
| Debt / Equity | 0.74× | 0.70× | 0.61× | 0.63× | 0.66× |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 8-K | 0001140361-26-038056 | Sep 30, 2026 | Sep 30, 2026 | Sep 30, 2026 11:12 UTC | EDGAR |
| 10-Q | 0001739940-26-000065 | Jun 30, 2026 | Jul 30, 2026 | Jul 30, 2026 16:37 UTC | EDGAR |
| 8-K | 0001140361-26-030135 | Jul 30, 2026 | Jul 30, 2026 | Jul 30, 2026 10:16 UTC | EDGAR |
| 8-K | 0001140361-26-020906 | May 13, 2026 | May 13, 2026 | May 13, 2026 10:01 UTC | EDGAR |
| 10-Q | 0001739940-26-000043 | Mar 31, 2026 | Apr 30, 2026 | Apr 30, 2026 15:47 UTC | EDGAR |
| 8-K | 0001140361-26-017971 | Apr 30, 2026 | Apr 30, 2026 | Apr 30, 2026 10:15 UTC | EDGAR |
| 8-K | 0001140361-26-017123 | Apr 22, 2026 | Apr 27, 2026 | Apr 27, 2026 20:26 UTC | EDGAR |
| 8-K | 0001140361-26-007450 | Feb 25, 2026 | Mar 3, 2026 | Mar 3, 2026 12:42 UTC | EDGAR |
Direct links to SEC EDGAR. CI has additional filings available on the SEC site.
6 numbers Cigna Group later changed — same XBRL tag, both filings linked.
Net Income (Loss) Attributable to Parent·3 months to Mar 2010
Notable restatementwas$283M
Revised down in a 8-K. Any P/E built on the original was 9.7% too low.
Net Income (Loss) Attributable to Parent·Q3 2011
Notable restatementwas$200M
Revised down in a 10-K. Any P/E built on the original was 9.3% too low.
Net Income (Loss) Attributable to Parent·3 months to Dec 2011
Notable restatementwas$290M
Revised down in a 10-K. Any P/E built on the original was 6.2% too low.
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest·FY 2011
Notable restatementwas$2B
Revised down in a 10-K.
Stockholders' Equity Attributable to Parent·As of Dec 31, 2010
Notable restatementwas$6.6B
Revised down in a 8-K.
Stockholders' Equity Attributable to Parent·As of Dec 31, 2011
Notable restatementwas$8.3B
Revised down in a 10-K.
CI is not the only one.
See every restatement we've found across the market — or get an alert the next time CI revises a number.
Restatements are detected by comparing every vintage of a fact across all of Cigna Group's filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows CI's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling Cigna Group — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on CI yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on CI and publish the result to your public profile.
Ask about Cigna Group
Continue in Workspace — cited answers on CI, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs